C

Corcept Therapeutics

develops cortisol-modulating therapies for Cushing's syndrome

Clinical Sales Specialist

Field SalesConfirmed live in the last 24 hours
Full-timeOld Bridge, NJ, USA$140k - $155k

About the Job

Requirements

  • A BA/BS or equivalent work experience is required.
  • At least 5 years of sales experience is required.
  • Applicants must be currently authorized to work in the United States on a full-time basis.
  • Maintain a driving record in accordance with Corcept vehicle policy.
  • Be able to lift and/or move up to 35 pounds.

Responsibilities

  • Build and develop professional relationships with influential high prescribers and thought leaders in the territory to enhance Corcept brand and product loyalty.
  • Leverage expertise and knowledge of the therapeutic disease state, marketplace, applicable competitors, industry, and cross-functional activities and plans to anticipate and effectively manage business opportunities and challenges.
  • Develop and implement effective customer-specific territory plans and communicate insights to internal stakeholders.
  • Prioritize time and effort to ensure optimal coverage of appropriate physician specialists based on opportunity and potential.
  • Plan and participate in education programs and speaker dinner programs.
  • Manage territory expenses and budget to support sales and marketing activities.

Desired Qualifications

  • Recent endocrine relationships are highly preferred.
  • Specialty therapeutic, hospital, or orphan drug sales experience is highly preferred.
  • Proven track record of consistent high performance.
  • Ability to collaborate and work cross-functionally.
  • Willingness to travel up to 100% of the time, including up to 40% overnight travel.

About the Company

Corcept Therapeutics

develops cortisol-modulating therapies for Cushing's syndrome

Corcept Therapeutics develops and commercializes cortisol modulators to treat disorders caused by abnormal cortisol levels. Its core product, Korlym (mifepristone), blocks cortisol’s action by acting as a cortisol receptor antagonist and is approved for hypercortisolism in Cushing’s syndrome. The company differentiates itself with a dedicated focus on cortisol modulation, an extensive pipeline of proprietary molecules, and ongoing development beyond Korlym. Its goal is to improve outcomes for patients with cortisol-related disorders by expanding access to effective therapies and advancing new treatments.

Company size
501-1,000
Company stage
IPO
Headquarters
Menlo Park, CA
Founded
1998

Recently Posted Jobs

Explore more opportunities at Corcept Therapeutics

See more jobs